Beginners Portfolio: Apple Inc Confounds The Critics

We have good news from Apple Inc (NASDAQ: AAPL) and GlaxoSmithKline (LON: GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article is the latest in a series that aims to help novice investors with the stock market. To enjoy past articles in the series, please visit our full archive.

The Beginners’ Portfolio is a virtual portfolio, which is run as if based on real money with all costs, spreads and dividends accounted for.

appleApple pulls it off

Ahead of a second-quarter earnings update from Apple (NASDAQ: AAPL.US) last night, the pundits were all predicting the same boring stuff — flat overall, with a modest rise in iPhone profits at best, iPad earnings falling, and entry-level products helping push down margins for Apple’s top-end offerings.

But the company surprised us all, reporting profits for the quarter of $10.2bn (£6.1bn) after selling an impressive 43.7 million iPhones in the period.

And in a move to return more of its cash to shareholders, Apple is to buy back a further $30bn of its own stock and bump its quarterly dividends by 8%. Oh, and there’ll be a seven-for-one stock split — the Beginners’ Portfolio will have 14 shares in place of the existing two.

Apple shares were up 8% in after-hours trading last night to $568.

gskA great deal for Glaxo

The other big portfolio news this week is the major deal between GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and Novartis, with the two companies combining to swap some assets and to pool some others.

Glaxo will transfer its cancer drugs portfolio to Novartis for $16bn (£9.5bn), with Novartis’s vaccines business making the opposite journey in exchange for $7.1bn.

The two firms are also big in the consumer products business, and they’re going to combine their offerings into a joint venture that should enjoy annual revenues of more than £6bn.

Glaxo reckons the net result of the deal will be a boost to its annual revenues of about £1.3bn.

The shares jumped 81p (5.2%) in response to the news yesterday, to 1,640p — and as I write today, the price is up to 1,658p.

TescoSteady at Tesco

I haven’t talked about last week’s results from Tesco (LSE: TSCO) yet, but it was very much “Everything as expected” with no surprises — and as if to confirm that, the share price has hardly budged and stands at 299p today.

Group sales were effectively flat — down 0.2% at constant exchange rates, up 0.3% at actual rates. There was a fall in underlying pre-tax profit of 6.9% to £3.05bn, which was very much in line with expectations.

We should still have a couple of years in the doldrums as far as earnings go, but with dividend yields set to reach 5%, I’m still happy to hold for the long term.

Alan does not own any shares mentioned in this article. The Motley Fool owns shares in Apple and Tesco, and has recommended shares in GlaxoSmithKline.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »